Eli Lilly (LLY) shares gain after Zepbound, the company's weight-loss drug, outperformed rival Novo Nordisk's (NVO) competing drug, Wegovy. Yahoo Finance Reporter Akiko Fujita breaks down the study and what it means for the weight-loss drug space.

To watch more expert insights and analysis on the latest market action, check out more Wealth here.

This post was written by Naomi Buchanan.